CELG - Amgen Blows Past EPS Estimates for the Second Quarter
What coronavirus? Amgen's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors.
The veteran biotech company booked revenue of nearly $6.21 billion in the second quarter, 6% higher on a year-over-year basis. Non-GAAP (adjusted) net profit rose by 4% to nearly $2.6 billion, or $4.25 per share.
Both of those line items topped analysts' consensus expectations. On average, prognosticators following the company were modeling for $6.18 billion on the top line, and an adjusted net profit of $3.84 per share.